The United States has obtained 300 million doses of the AstraZeneca COVID-19 experimental vaccine (File)
AstraZeneca has received support from the United States government to advance the development of COVID-19 antibody treatments as the British drug maker steps up efforts beyond its potential vaccine to fight the global health crisis.
The company said on Tuesday that it has signed a second round of agreements with US officials to support its development of a monoclonal antibody treatment for the coronavirus.
He declined to release details of the deal, but said he had agreed to conditions with the Defense Advanced Research Projects Agency (DARPA) and the Biomedical Advanced Research and Development Authority (BARDA) to displace two COVID-19 antibody therapies that he has authorized from researchers in clinical studies. in the next two months.
Businesses and governments are working to bring a solution to the disease caused by the new coronavirus to the market as soon as possible, and many in the medical community believe that antibody-based therapies have great potential.
The United States has already obtained 300 million doses of AstraZeneca’s COVID-19 experimental vaccine, AZD1222, and Defense Secretary Mark Esper promised last month that the U.S. military and other parts of the government would work with the private sector to produce a large-scale vaccine by the end of the year.
AstraZeneca said it has licensed six monoclonal antibody candidates from Vanderbilt University in Nashville, Tennessee. Two of these six prospective proteins will be tested as a combined approach for COVID-19.
Antibodies are generated in the body to fight the infection. Monoclonal antibodies mimic natural antibodies and can be isolated and produced in large quantities to treat patients’ illnesses.
The shares of the most valuable listed company in London rose 1.3% to 8,307 pence at 11:14 GMT.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
